Q3. What are the prospects for the industry going forward?
1.Though the average level of profitability in the pharmaceutical industry has been declining over time (In 2002, the average ROIC in the industry was 21.6%; by 2006, it had fallen to 14.5%), historically, the pharmaceutical industry has been a profitable one. Because-
Name of industry | Average ROIC(Between 2002 and 2006) | Pharmaceuticals | 16.45%(large) | computer hardware | 12.76% | Electronics | 3.88% |
2. The prospect for the industry for going forward is very positive. Because the demand for pharmaceuticals has been strong and has grown for decades. Between 1990 and 2003, there was a 12.5% annual increase in spending on prescription drugs in the United
…show more content…
Develop unique molecule: Develop unique molecule that cures better than other drugs so that any company can charge premium price for their drugs.
2. Develop new drugs for intractable medical conditions: Develop new drugs that treat some of the most intractable medical conditions, including cancer, heart disease, stroke, and AIDS. They can replace revenues from drugs going off patent by these new drugs.
3. Before launching a drugs prescribed for curing one kind of disease, companies can test the new drags carefully so that the new drags will not be a reason for other diseases
Q2. After 2002, the profitability of the industry, measuredby ROIC, started to decline. Why do you think thisoccurred?
the average level of profitability in the pharmaceutical industry has been declining over time(In 2002, the average ROIC in the industry was 21.6%; by 2006, it had fallen to 14.5%).
Reasons for declining:
1. Lose of patent protection: twelve of the thirty-five top-selling drugs in the industry were to lose their patent protection between 2006 and 2009. So the companies have to develop enough new drugs in their pipelines to replace revenues from drugs going off patent.So investment in R&D will have to increase.It’svery difficult because Only very large companies can shoulderthe costs and risks of doing R&D. and most importantly Out of every 5,000 compounds tested in the laboratoryby a drug company, only five enter
Phase 3 clinical studies - Intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.
Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and
2. Patent related and Generic Competition: The developed countries like US and Europe have strong patent protection laws which gives a lot of benefits for the pharmaceutical companies. But, the patent
U.S. based companies hold rights to most of the world’s rights on new medicines and holds thousands of new products currently being developed. As of 2012, the industry helps support almost 3.4 million jobs in the U.S. economy. It is also one of the most heavily R&D based industries in the world. In the United States, the environment for pharmaceuticals is much friendlier than other countries around the world in terms of pricing ability and regulations. Both the Pharmaceutical and Biotechnology industries have experienced significant growth in the past year with year-over-year increases of 13.02% and 34.69% respectively. It is an even more striking when looking at the past five years considering both have beat out the S&P 500 with pharmaceuticals increasing an additional 31.44% and the biotechnology sector besting an astonishing 269.3% more return than the
Returns in the Pharmaceutical Industry (Washington, D.C.: Congressional Budget Office, July 1998). This report may be accessed from http://www.cbo.gov.
prescription drugs, which will play a big role in the increase of profits for pharmaceutical
Extremely risky drug discovery and development, lengthening development times which increase development cost, return on investments, and generic competitors.
3. No new drugs are to be available in the market for this indication in the next 5 years so it makes the product very lucrative.
Prescription drug prices rose three times faster than inflation in the decade between 1981 and 1991, making the pharmaceutical industry the nation's most profitable business. Prescription drugs even exceeded the rapidly rising inflation rate for all other medical services. They now represent at least 10% of all the medical
A lot of people, particularly the patients who need them, are beginning to wonder why American drug prices are so high. It makes sense why the pharmaceutical companies are selling at the prices they do: they are a business; and they want to, above all else, make a profit. But the real question is: what are all of the
The pharmaceutical industry includes companies that research, develop, market or distribute generic and branded drugs. The industry expanded during the 1980’s and drugs to treat heart disease and AIDS were prominent. Consumer demand for nutritional supplements and alternative medicine increased during the 1990’s with the Internet facilitating direct purchases of drugs. Advertising for direct consumption of pharmaceutical drugs became more prominent; pharmaceutical companies were criticized for over medicating personality or social problems.
We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.
* Large Balance, $1.4B in goodwill on Merck’s Balance Sheet – the goodwill on Merck’s balance sheet is primarily attributable to past acquisitions.
The research and development of the pharmaceutical industry is very important as the industry relies on it to develop new products to maintain and sustain the growth of the industry (ALRC 2014). According to the Australian Government Law Reform Commission, every year, the total spending in research and development in pharmaceutical industry, which includes drug discovery, pre-clinical testing and clinical trials on drugs is around $300 million (ALRC 2014). Mergers and acquisitions are intensifying in the global pharmaceutical industry, especially over the last 10 years. With factors like exorbitant research and development costs, the relatively shorter product life cycles, and the rarity of discovering a new life-changing drug acting as catalysts, leading pharmaceutical companies now have more cause to step out and look for external collaboration. This results in an increasing number of smaller biotechnology companies merging with bigger pharmaceutical companies (The
Although R&D has been retained by the large pharmaceutical firms, there has been a continuous decline in the R&D productivity. Controlling R&D is imperative to the success of a Pharmaceutical firm. However, as the pharmaceutical industry is maturing, there are diminishing returns to the R&D investment. Fewer and fewer blockbuster drugs are being discovered and therefore R&D is not the most value adding component in the value